The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
TEVIMBRA Beigene Aus Pty Ltd
Product name
TEVIMBRA
Sponsor
Accepted date
Apr-2024
Active ingredients
tislelizumab
Proposed indication
Indicated for the first-line treatment of locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma.
Application type
A (new medicine)
Publication date
Apr-2024